Video

Promise in Pancreatic Cancer

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Picture of Dr. Pouneh Razavi
Image of a woman wearing a headband and glasses
Image of doctor.
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Related Content
CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study: © stock.adobe.com.
April 30th 2025

CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer

Spencer Feldman
CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
The FDA granted approval to treatment with Tepylute at 100 mg for breast and ovarian cancers: © stock.adobe.com.
April 29th 2025

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

Spencer Feldman
The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
The first patient has been dosed in a phase 1/2 trial investigating treatment with AP402, a T-cell engager, for patients with HER2-positive cancers: stock.adobe.com.
April 23rd 2025

First Patient Dosed with AP402 in a Trial for HER2 Advanced Tumors

Spencer Feldman
The combination of Enhertu plus Perjeta showed improvement in progression-free survival versus standard treatment among patients with HER2-positive metastatic breast cancer.
April 21st 2025

Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer

Ryan Scott
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.